Evaluation of the Roche SARS-CoV-2 Rapid Antibody Test in Samples from Vaccinated Individuals

Hayer, Johannes; Urlaub, Eva

doi:10.1128/spectrum.02709-21

Cited by 3 publications

(3 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several other studies [12] , [13] , [14] , [15] , [16] , [17] , [18] , [19] , [20] , [21] , [22] , [23] , [24] , [25] , [26] , [27] , [28] , [29] , [30] , [31] , [32] have also ascertained clinical sensitivity of the assay after exposure to the SARS-CoV-2 virus or vaccine or both, and specificity through evaluation of pre-pandemic specimens. Sensitivities have been reported at time intervals varying from 14 days to 240 days post-exposure.…”

Section: Resultsmentioning

confidence: 99%

Utility of Roche Elecsys anti-SARS-CoV-2 S in ascertaining post-vaccine neutralizing antibodies

Aijaz¹,

Kanani²,

Naseer³

2023

Journal of Clinical Virology Plus

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Utility of Roche Elecsys anti-SARS-CoV-2 S in ascertaining post-vaccine neutralizing antibodies

Aijaz¹,

Kanani²,

Naseer³

2023

Journal of Clinical Virology Plus

View full text Add to dashboard Cite

“…We also used the SARS‑CoV‑2 Rapid Antibody Test, a rapid chromatographic immunoassay intended for the qualitative in vitro detection of antibodies to SARS‑CoV‑2 in human serum, plasma or whole blood. The rapid antibody test detects IgG and IgM antibodies against S and N combined 51 , 52 and was performed at the University Hospital Frankfurt laboratory.…”

Section: Methodsmentioning

confidence: 99%

Kinetics of SARS-CoV-2 infection biomarkers in a household transmission study

Groh,

Vehreschild,

Diaz

et al. 2024

Sci Rep

View full text Add to dashboard Cite

SARS-CoV-2 is the causative agent of COVID-19. Timely and accurate diagnostic testing is vital to contain the spread of infection, reduce delays in treatment and care, and inform patient management. Optimal specimen type (e.g. nasal swabs or saliva), timing of sampling, viral marker assayed (RNA or antigen), and correlation with viral infectivity and COVID-19 symptoms severity remain incompletely defined. We conducted a field study to evaluate SARS-CoV-2 viral marker kinetics starting from very early times after infection. We measured RNA and antigen levels in nasal swabs and saliva, virus outgrowth in cell culture from nasal swabs, and antibody levels in blood in a cohort of 30 households. Nine household contacts (HHC) became infected with SARS-CoV-2 during the study. Viral RNA was detected in saliva specimens approximately 1–2 days before nasal swabs in six HHC. Detection of RNA was more sensitive than of antigen, but antigen detection was better correlated with culture positivity, a proxy for contagiousness. Anti-nucleocapsid antibodies peaked one to three weeks post-infection. Viral RNA and antigen levels were higher in specimens yielding replication competent virus in cell culture. This study provides important data that can inform how to optimally interpret SARS-CoV-2 diagnostic test results.

show abstract

“…Anti-RBD and anti-N total binding antibody titers were assessed by the Elecsys anti-SARS-CoV-2 S immunoassay on a Roche Cobas 6000 (Roche Diagnostics) according to the manufacturer’s instructions. The analyte concentration of each sample was expressed in U/mL and E/S for anti-RBD and anti-N total binding antibodies, respectively [ 16 ]. SARS-CoV-2 neutralizing antibodies (nAbs) against the Wuhan-Hu-1 strain and the B.A.1.1.529 (Omicron) variant were measured with the GenScript kit (cPass, Piscataway, NJ, USA), a surrogate virus neutralization test (sVNT) whose accuracy was reported elsewhere and results were expressed as inhibition rate (%) and in IU/mL based on WHO international standards [ 17 , 18 ].…”

Section: Methodsmentioning

confidence: 99%

First Detection of the SARS-CoV-2 Omicron BA.5/22B in Monaco

et al. 2022

View full text Add to dashboard Cite

The Omicron BA.5/22B variant has been designated as a “variant of concern” by the World Health Organization. We describe, here, the first evidence in Monaco of infection with an Omicron BA.5/22B variant, probably imported from the Republic of Seychelles, harboring a rare combination of non-BA.5/22B signature amino acid changes. SARS-CoV-2 neutralizing antibodies were measured with a surrogate virus neutralization test. SARS-CoV-2 genotype screening was performed on nasopharyngeal samples with a multiplex qPCR assay. The SARS-CoV-2 genome was obtained by next-generation sequencing with the Illumina COVID-seq protocol, then assembly using bioinformatics pipelines and software was performed. The BA.5/22B spike protein structure was obtained by molecular modeling. Two spouses were SARS-CoV-2-diagnosed the day they returned from a one-week trip in the Republic of Seychelles. SARS-CoV-2 qPCR screening for variant-specific mutations identified an Omicron variant BA.1/21K, BA.4/22A, or BA.5/22B. A SARS-Co-2 BA.5/22B variant genome was recovered from one of the spouses. Aside from BA.5/22B-defining amino acid substitutions, four other amino acid changes were encoded including Q556K in ORF1a, K2557R in ORF1b, and A67V and A829T in spike; only 13 genomes in sequence databases harbored these four mutations concurrently. Structural analysis of this BA.5/22B variant predicted that A829T in spike may result in a compaction that may affect conformational plasticity. Overall, our findings warrant performing genome-based genotypic surveillance to survey accurately the emergence and circulation of SARS-CoV-2 variants worldwide and point out that their first occurrence in a country is often through international travel despite implemented countermeasures.

show abstract

Evaluation of the Roche SARS-CoV-2 Rapid Antibody Test in Samples from Vaccinated Individuals

Cited by 3 publications

References 39 publications

Utility of Roche Elecsys anti-SARS-CoV-2 S in ascertaining post-vaccine neutralizing antibodies

Utility of Roche Elecsys anti-SARS-CoV-2 S in ascertaining post-vaccine neutralizing antibodies

Kinetics of SARS-CoV-2 infection biomarkers in a household transmission study

First Detection of the SARS-CoV-2 Omicron BA.5/22B in Monaco

Contact Info

Product

Resources

About